NG-350A Combination Therapy Shows Promise in Rectal Cancer Trial

Akamis Bio has reported positive early results from a Phase Ib clinical study evaluating the oncolytic immunotherapy NG-350A alongside chemoradiotherapy (CRT) in patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC).

The open-label, multi-centre trial recorded a 50% composite response rate among the first ten participants who completed the 12-week treatment period, with no serious safety concerns or adverse effects attributed to NG-350A. The study is designed to determine whether combining NG-350A with CRT can improve outcomes compared to standard CRT alone.

The primary endpoint focuses on the proportion of patients achieving clinical complete response or near-complete response at 12 weeks. These early findings align with results from a prior study using a related therapy.

The trial plans to enrol 30 adults and will also evaluate tumour response, safety, and circulating tumour DNA levels, with recruitment expected to finish in 2026.

20-04-2026